Credit Suisse Ag Rubius Therapeutics, Inc. Transaction History

Credit Suisse Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.79 - $5.98 $22,588 - $170,986	-28,593 Reduced 99.92%	24 $0
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $7,407 - $18,127	1,743 Added 6.49%	28,617 $158,000
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $10,560 - $19,354	1,091 Added 4.23%	26,874 $259,000
Q3 2021 Nov 12, 2021	BUY	$17.6 - $25.91 $27,332 - $40,238	1,553 Added 6.41%	25,783 $461,000
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $89,017 - $113,691	3,999 Added 19.77%	24,230 $592,000
Q1 2021 May 14, 2021	SELL	$8.02 - $32.01 $91,748 - $366,194	-11,440 Reduced 36.12%	20,231 $536,000
Q4 2020 Feb 12, 2021	BUY	$4.23 - $8.73 $62,375 - $128,732	14,746 Added 87.13%	31,671 $240,000
Q3 2020 Nov 13, 2020	SELL	$4.65 - $6.25 $14,866 - $19,981	-3,197 Reduced 15.89%	16,925 $84,000
Q2 2020 Aug 12, 2020	BUY	$4.01 - $6.88 $16,561 - $28,414	4,130 Added 25.83%	20,122 $121,000
Q1 2020 May 13, 2020	SELL	$3.74 - $9.84 $1,754 - $4,614	-469 Reduced 2.85%	15,992 $71,000
Q4 2019 Feb 12, 2020	SELL	$7.23 - $14.12 $38,731 - $75,640	-5,357 Reduced 24.55%	16,461 $156,000
Q3 2019 Nov 12, 2019	BUY	$7.85 - $15.75 $36,816 - $73,867	4,690 Added 27.38%	21,818 $171,000
Q2 2019 Aug 14, 2019	BUY	$13.5 - $19.94 $231,228 - $341,532	17,128 New	17,128 $269,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.